| Name | Title | Contact Details |
|---|---|---|
Robert Martino |
Associate Director of Compliance | Profile |
Jerry Diffley |
Chief Compliance and Privacy Officer | Profile |
Fayyaz Memon |
Vice President Regulatory Affairs | Profile |
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! Our employees can be found collaborating across the United States, Europe and Asia. As a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases.
Complete Genomics is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blue River Systems is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ellipsis Biotherapeutics Corporation is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Gritstone Oncology is a privately-held company headquartered in the San Francisco Bay Area with key functions located in Cambridge, Massachusetts and Pleasanton, California. We launched in October 2015, and since inception, have successfully raised two large, private financing rounds. We currently employ more than 60 professionals. We have brought together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy. With our unique approach to immuno-oncology, we are developing next-generation personalized immunotherapies to fight cancer in patients with the most difficult-to-treat tumors. We plan to combine these personalized neoantigen-targeted therapies with current immune checkpoint modulatory approaches to improve response rates and survival in patients with solid tumors.